32 results
424B3
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
to determine safety and potential efficacy of intravenously administered autologous SVF cells in patients with severe, immune suppressive refractory … aplastic anemia with the primary endpoints of safety and feasibility and secondary endpoints of efficacy as determined by patients having complete
424B3
RGBP
Regen BioPharma Inc
2 Oct 23
Prospectus supplement
1:42pm
and supporting information to establish the product candidate’s safety and effectiveness for each desired indication. NDAs and BLAs must also include … . Each phase exposes greater number of subjects to the drug and each phase builds on existing safety and efficacy information. Phase 1 trials
8-K
EX-10.1
tnxb28q 0q
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
424B3
jmehmpb9634p2m bso7
15 May 23
Prospectus supplement
10:25am
8-K
EX-10.1
mtdgm qrv7kh
8 Apr 21
Entry into a Material Definitive Agreement
10:08am
8-K
EX-10.2
2jexesa 4e2
8 Apr 21
Entry into a Material Definitive Agreement
10:08am